Precision BioSciences to Participate in Upcoming Jefferies Cell & Genetic Medicine Summit
September 22 2022 - 7:00AM
Business Wire
Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage gene
editing company developing ARCUS®-based ex vivo allogeneic CAR T
and in vivo gene editing therapies, today announced that the
Company will participate in the Jefferies Cell & Genetic
Medicine Summit taking place September 29-30, 2022.
Details for the company presentation are as follows:
Date: Friday, September 30, 2022 Time: 2:00 PM ET Location: Lotte
New York Palace Hotel
The presentation will be available via a recorded webcast
accessible on Precision’s website in the Investors section under
Events & Presentations:
https://investor.precisionbiosciences.com/events-and-presentations.
An archived replay will be available for approximately 30 days
following the event.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology
company dedicated to improving life (DTIL) with its novel and
proprietary ARCUS® genome editing platform. ARCUS is a highly
precise and versatile genome editing platform that was designed
with therapeutic safety, delivery, and control in mind. Using
ARCUS, the Company’s pipeline consists of multiple ex vivo
“off-the-shelf” CAR T immunotherapy clinical candidates and several
in vivo gene editing candidates designed to cure genetic and
infectious diseases where no adequate treatments exist. For more
information about Precision BioSciences, please visit
www.precisionbiosciences.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220922005120/en/
Investor Contact: Mei Burris Director, Investor Relations
& Finance Mei.burris@precisionbiosciences.com
Media Contact: Maurissa Messier Senior Director,
Corporate Communications
Maurissa.Messier@precisionbiosciences.com
Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From Apr 2023 to Apr 2024